Earnings Summary

Aclaris Therapeutics Inc’s revenue jumped 126.62% since last year same period to $17.57Mn in the Q4 2023. On a quarterly growth basis, Aclaris Therapeutics Inc has generated 89.29% jump in its revenue since last 3-months.

Aclaris Therapeutics Inc’s net profit jumped 95.52% since last year same period to $-1.49Mn in the Q4 2023. On a quarterly growth basis, Aclaris Therapeutics Inc has generated 94.9% jump in its net profits since last 3-months.

Aclaris Therapeutics Inc’s net profit margin jumped 98.02% since last year same period to -8.49% in the Q4 2023. On a quarterly growth basis, Aclaris Therapeutics Inc has generated 97.31% jump in its net profit margins since last 3-months.

Aclaris Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.29 - a 14.71% jump from last quarter’s estimates.

Aclaris Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.29.

Aclaris Therapeutics Inc’s earning per share (EPS) jumped 95.12% since last year same period to -0.02 in the Q4 2023. This indicates that the Aclaris Therapeutics Inc has generated 95.12% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Aclaris Therapeutics Inc’s return on assets (ROA) stands at -0.33.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Aclaris Therapeutics Inc’s return on equity (ROE) stands at -0.5.